Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So
This article was originally published in PharmAsia News
SHANGHAI - China could serve as the catalyst for a new model of dealmaking that emphasizes more flexible and strategic partnerships to drive R&D productivity, but only if Big Pharma is willing to take "calculated risks," according to Bayer Healthcare AG Chairman Jorg Reinhardt
You may also be interested in...
Bayer HealthCare signed a deal with Peking University to establish a joint research center in Beijing to strengthen its R&D capability in China.
Pfizer’s Olivier Brandicourt, who has specialized in emerging markets and infectious diseases, inherits Bayer’s health care division, which is in the midst of several product launches and has few near-term patent expirations. Bayer has one of the largest exposures to emerging markets among large pharma companies.
On the sidelines of the recent J.P. Morgan Healthcare Conference, Merck’s chief strategy officer discusses his company’s strategy in China – or does he?